Posted by Michael Wonder on 09 Jun 2023
US FDA approves FoundationOne Liquid CDx as a companion diagnostic for Pfizer’s Braftovi (encorafenib) in combination with cetuximab to identify patients with BRAF V600E alterations in metastatic colorectal cancer
9 June 2023 - Foundation Medicine today announced that it has received approval from the US FDA for FoundationOne Liquid CDx to be used as a companion diagnostic for Braftovi (encorafenib) in combination with cetuximab which is currently FDA approved for adult patients with previously treated metastatic colorectal cancer harbouring a BRAF V600E alteration.
This now makes FoundationOne Liquid CDx the only comprehensive genomic profiling test FDA approved to identify patients with BRAF V600E alterations in metastatic colorectal cancer who may be appropriate for treatment with Braftovi in combination with cetuximab.
